SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scott_jiminez who started this subject7/16/2000 4:53:07 AM
From: scott_jiminez  Read Replies (2) of 278
 
Regarding Memantine and Alzheimer's disease...

In the recent press release by Neurobiological Technologies (NTII) regarding the recent PIII results of Memantine on moderate to advanced AD patients, there was the following statement:

``This has been an exciting and encouraging study on many fronts. Not only was this perhaps the first study to find cognitive and functional treatment effects for people with this severity of disease, but our research provided further evidence that modulation of the NMDA receptor, involved in memory and neuronal death, is an approach worthy of continued research.''

For those with little scientific or historical background in this field (which applies to, as far as I can discern, ALL of the relevant posts I've read on SI), this data sounds groundbreaking. This is an unfortunate and poorly informed perspective. Turn the clock back 15-20 years and you will find Peter Davies (Einstein/Bronx) voicing strikingly similar claims regarding the cholinergic system. In fact, telescope the last 2-3 decades and you'll find flash-in-the-pan claims for virtually every known neurotransmitter system.

I don't question that NMDA receptor effectors will have a small (and likely transient) effect in a subpopulation of AD patients. Trust me, these scenarios are played out almost on an annual basis. Just change the nomenclature in the press release and present it again next year.

Far from being immune to hype, Biotech rewrote the book.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News